Investing.com - Adaptimmune Therapeutics (NASDAQ:ADAP) reported on Thursday fourth quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
Adaptimmune Therapeutics announced earnings per share of $-0.04 on revenue of $1.5M. Analysts polled by Investing.com anticipated EPS of $-0.2333 on revenue of $1.8M.
Adaptimmune Therapeutics shares are up 11.13% from the beginning of the year, still down 55.30% from its 52 week high of $13.40 set on June 1, 2020. They are outperforming the Nasdaq which is up 5.51% from the start of the year.
Adaptimmune Therapeutics shares gained 0.67% in pre-market trade following the report.
Adaptimmune Therapeutics follows other major Healthcare sector earnings this month
Adaptimmune Therapeutics's report follows an earnings missed by Roche Holding ADR on February 1, who reported EPS of $1.21 on revenue of $15.88B, compared to forecasts EPS of $1.28 on revenue of $16.45B.
Abbott Labs had beat expectations on January 27 with fourth quarter EPS of $1.45 on revenue of $10.7B, compared to forecast for EPS of $1.35 on revenue of $9.94B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar